{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.","groups":[{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG000","title":"Part 2"}],"populationDescription":"No participants in Part 2 of the study had a complete or partial response to study treatment.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.","title":"Part 2: Median DoR Per Investigator Assessment of RECIST 1.1 Criteria","type":"SECONDARY"}